MYELOFIBROSIS

This study allows people who were already receiving itacitinib in previous clinical trials to continue taking the medication. It's for adults with myelofibrosis, chronic graft-versus-host disease, or lung transplant complications who were benefiting from the drug in earlier studi…

This study is testing whether a new drug called imetelstat helps people with advanced myelofibrosis live longer compared to currently available treatments. It's for patients whose disease has worsened or didn't respond to standard JAK inhibitor medications. About 327 participants…

This study is testing whether adding a new drug called selinexor to an existing standard drug (ruxolitinib) works better for people newly diagnosed with myelofibrosis, a serious bone marrow cancer. The main goals are to see if the combination shrinks enlarged spleens more effecti…

This study is testing a new drug called BMS-986158 for people with intermediate or high-risk myelofibrosis, a serious blood cancer. Researchers want to see if the drug is safe and works better when given alone or combined with two other approved myelofibrosis medications. The tri…

This study is testing if using a lower dose of a standard drug (cyclophosphamide) given after a stem cell transplant can reduce serious infections in the first 100 days. The trial aims to see if this lower dose is just as good at preventing graft-versus-host disease, a common and…

This study aims to find out which treatment works better for people with high-risk myelofibrosis, a serious bone marrow cancer. Participants choose between a stem cell transplant (which could cure the disease but has serious risks) or the best available non-transplant drug therap…

This early-stage trial is testing whether a combination of two immune-based treatments is safe for patients whose blood cancer has returned after a stem cell transplant. The study involves 25 adults with conditions like acute myeloid leukemia or myelodysplastic syndromes. Researc…

This is a first-in-human study to find a safe dose of an experimental antibody drug called Hu8F4 for patients with advanced blood cancers like leukemia and myelodysplastic syndrome (MDS). The main goals are to check for side effects and see how the body processes the drug. The st…

This study is testing a specific type of stem cell transplant for patients with various blood cancers. It uses stem cells from a partially matched family donor instead of bone marrow. The main goals are to see how well patients survive and recover, and to learn how the immune sys…

This early-stage study aims to find a safe dose for a new combination of three drugs (navitoclax, venetoclax, and decitabine) to treat aggressive forms of blood and bone marrow cancers. It will enroll about 36 adults with specific high-risk conditions like acute myeloid leukemia …

This large, late-stage trial is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for people newly diagnosed with myelofibrosis, a serious bone marrow cancer. The study will see if the combination shrinks enlarged spleens mor…

This study is testing if adding a new drug called veliparib to a standard two-drug chemotherapy works better for people with advanced blood cancers that have spread and are hard to treat. It will compare the two-drug combo with the three-drug combo in about 25 participants to see…

This early-stage study is testing a new drug called INCB057643, both alone and in combination with an existing drug (ruxolitinib), in adults with advanced blood cancers like myelofibrosis. The main goal is to check if the treatment is safe and tolerable. Researchers will also loo…

This study is testing whether adding the drug thalidomide to the standard drug ruxolitinib works better for people with myelofibrosis, a rare bone marrow cancer. It aims to see if the combination can shrink the cancer and improve problems like anemia, enlarged spleen, and other s…

This study is testing an oral drug called selinexor for people with myelofibrosis, a serious bone marrow cancer, who have already tried and stopped responding to standard JAK inhibitor treatments. About 112 participants will be randomly assigned to receive either selinexor or the…

This study is testing a new approach to prevent a common and dangerous viral infection called CMV in people receiving a stem cell transplant for blood cancer. Researchers are giving a vaccine to the healthy stem cell donors before the transplant. The goal is to see if the donor's…

This study is testing a vaccine designed to prevent cytomegalovirus (CMV) infection in adults with blood cancers who are receiving a half-matched stem cell transplant. CMV is a common virus that can become life-threatening when the immune system is weakened after transplant. The …

This study is observing 40 patients with a bone marrow cancer called myelofibrosis who are already taking the drug gecacitinib from previous trials. Researchers are not giving any new treatment; they are simply collecting yearly bone marrow and blood samples to see how the diseas…